Skip to Content
Merck
  • MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1.

MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1.

Molecular and cellular biology (2014-09-10)
Sriganesh B Sharma, Chen-Chung Lin, Mark K Farrugia, Sarah L McLaughlin, Emily J Ellis, Kathleen M Brundage, Mohamad A Salkeni, J Michael Ruppert
ABSTRACT

Despite the low prevalence of activating point mutation of RAS or RAF genes, the RAS-extracellular signal-regulated kinase (ERK) pathway is implicated in breast cancer pathogenesis. Indeed, in triple-negative breast cancer (TNBC), there is recurrent genetic alteration of pathway components. Using short hairpin RNA (shRNA) methods, we observed that the zinc finger transcription factor Krüppel-like factor 4 (KLF4) can promote RAS-ERK signaling in TNBC cells. Endogenous KLF4 bound to the promoter regions and promoted the expression of two microRNAs (miRs), miR-206 and miR-21 (i.e., miR-206/21). Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the pathway suppressors RASA1 and SPRED1. In TNBC cells, including cells with mutation of RAS, the suppression of either RASA1 or SPRED1 increased the levels of GTP-bound, wild-type RAS and activated ERK 1/2. Unlike the control cells, treatment of RASA1- or SPRED1-suppressed cells with anti-miR-206/21 had little or no impact on the level of activated ERK 1/2 or on cell proliferation and failed to suppress tumor initiation. These results identify RASA1 and SPRED1 mRNAs as latent RAS-ERK pathway suppressors that can be upregulated in tumor cells by anti-miR treatment. Consequently, KLF4-regulated miRs are important for the maintenance of RAS-ERK pathway activity in TNBC cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-HA antibody, Mouse monoclonal, clone HA-7, purified from hybridoma cell culture
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting human MARCH8
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting human MYLIP
Pricing and availability is not currently available.
Supelco
Glutathione, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Glutathione, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting mouse March8
Pricing and availability is not currently available.
Sigma-Aldrich
5-Aza-2′-deoxycytidine, ≥97%
Pricing and availability is not currently available.
Sigma-Aldrich
L-Glutathione reduced, ≥98.0%
Pricing and availability is not currently available.
Sigma-Aldrich
L-Glutathione reduced, suitable for cell culture, BioReagent, ≥98.0%, powder
Pricing and availability is not currently available.
Sigma-Aldrich
L-Glutathione reduced, BioXtra, ≥98.0%
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting human MLXIP
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Mlxip
Pricing and availability is not currently available.